Oncologic Staging with<sup>68</sup>Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than<sup>18</sup>F-FDG PET/CT
Tristan T. Demmert(Essen University Hospital), Wolfgang P. Fendler(Essen University Hospital), Lale Umutlu(Essen University Hospital), Kim M. Pabst(West German Heart and Vascular Center Essen), Katharina Lueckerath(German Cancer Research Center), Helena Lanzafame(Essen University Hospital), Jens T. Siveke(German Cancer Research Center), Hubertus Hautzel(Deutsches Konsortium für Translationale Krebsforschung), Ken Herrmann(Essen University Hospital), Rainer Hamacher(Essen University Hospital), Kelsey L. Pomykala
Cited by 23
Related Papers
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
|Nature Medicine|2015|414
Radiotheranostics: a roadmap for future development
|The Lancet Oncology|2020|306